Oak Bay Biosciences develops gene therapies targeting inherited retinal diseases by utilizing adeno-associated virus (AAV) vectors for precise gene delivery. Their approach aims to restore vision by addressing the underlying genetic mutations that cause these conditions.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inherited retinal diseases, caused by genetic mutations, lead to progressive vision loss and blindness. Current treatments are limited, and many patients lack effective options to address the underlying genetic causes of their condition. The need for targeted therapies that can restore visual function at the genetic level remains unmet.
Solution
Oak Bay Biosciences is developing gene therapies for inherited retinal diseases using adeno-associated virus (AAV) vectors to deliver functional genes directly to retinal cells. This approach aims to correct the underlying genetic defects responsible for these diseases, potentially restoring or preserving vision. By targeting specific mutations, Oak Bay Biosciences seeks to provide personalized and effective treatments for patients with inherited retinal disorders. The AAV vectors are designed for efficient and safe gene transfer, minimizing off-target effects and maximizing therapeutic benefit.
Target Audience
The primary target audience includes patients diagnosed with inherited retinal diseases caused by specific genetic mutations, as well as ophthalmologists and retinal specialists seeking advanced therapeutic options.
Features
- AAV vector-based gene delivery for targeted gene replacement or augmentation
- Focus on inherited retinal diseases caused by specific genetic mutations
- Development of personalized gene therapies tailored to individual patient genotypes
- Preclinical studies evaluating the safety and efficacy of gene therapy candidates
- Research on novel AAV capsid variants for improved retinal cell transduction